title: Use of benchmarking in the development of biopharmaceutical products.
abstract: As the pharmaceutical and biotechnology industry enters the 21st century, the pressure on companies to maintain the level of productivity required for consistent year-on-year growth is increasing. Benchmarking has become a tool for obtaining the information needed to support continuous improvement and gain a competitive advantage. During the process of benchmarking, best practices can be identified while giving management the ability to improve on existing performance in an objective, well-informed manner. When used appropriately, benchmarking provides a new perspective on traditional methods while enabling companies to monitor their performance.
authors.affiliation: Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. mgiffin@amgen.com
authors.forename: Marian
authors.initials: M
authors.lastname: Giffin
authors.forename: Sally
authors.initials: S
authors.lastname: McLeish
mesh_terms: D019985:Benchmarking / Q000379:methods* / Q000458:organization & administration / Q000592:standards* / Q000639:trends; D001702:Biopharmaceutics / Q000331:legislation & jurisprudence / Q000379:methods* / Q000592:standards* / Q000639:trends; D017277:Drug Approval / Q000379:methods*; D004345:Drug Industry / Q000379:methods* / Q000592:standards*; D007880:Legislation, Drug / Q000592:standards; D004364:Pharmaceutical Preparations / Q000592:standards*; D011786:Quality Control; D014481:United States
chemical_list: D004364:Pharmaceutical Preparations